Sunday , December 5 2021

Patients with NCI-MATCH with AKT1-mutant cancer respond well to AstraZeneca drugs.



[ad_1]

  1. AKT1 – NCI-MATCH patients with mutant cancer, respond well to AstraZeneca Drug GenomeWeb
  2. Drug-tailored drugs based on oncologic genetic testing are effective EurekAlert (press release)
  3. All Press

[ad_2]
Source link